Goldman Sachs
CRBP icon

Goldman Sachs’s Corbus Pharmaceuticals CRBP Stock Holding History

Goldman Sachs’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,000
Closed -$526K – 5182
2018
Q4 		$526K Buy
3,000
+1,667
+125% +$333K ﹤0.01% 4336
2018
Q3 		$302K Buy
+1,333
New +$216K ﹤0.01% 4711

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's CRBP Position: Q1 2026 in Review

Goldman Sachs increased its Corbus Pharmaceuticals (CRBP) stake by 96% in Q1 2026, buying an estimated $385K and bringing the position to 93,111 shares worth $874K. The position accounts for ﹤0.01% of the portfolio, ranked #5181.

Goldman Sachs first reported a position in CRBP in Q4 2017 and has held it in 28 quarters since. The position peaked at $4.17M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Goldman Sachs held 93,111 shares of Corbus Pharmaceuticals worth $874K as of Q1 2026.
  • Goldman Sachs bought 45,673 Corbus Pharmaceuticals shares in Q1 2026, an estimated $385K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5181 holding.
  • Goldman Sachs first reported a position in Corbus Pharmaceuticals in Q4 2017 and has held it in 28 quarters since.
  • Goldman Sachs's Corbus Pharmaceuticals position peaked at $4.17M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.